Captek Softgel International acquires J+D Labs
J+D Labs’ extensive experience manufacturing a wide-range of softgels, specialized tablets, capsules, and powder formulations complements Captek’s offerings.
California-based Captek Softgel International (CSI) has acquired J+D Labs Pharma Manufacturing. CSI is a portfolio company of Swander Pace Capital (SPC), and the acquisition of J+D Labs is a continuation of SPC’s focus on investing in and growing industry-leading vitamin, mineral, and supplement companies.
For decades J+D Labs has been well recognized in the nutraceutical industry as a first-class manufacturer of health and wellness supplements producing more than 1,000 unique formulations. More recently J+D Labs has brought NutraStock to the market, more than 250 bulk stock dietary supplements manufactured in the US.
Captek CEO David Wood said this union will result in a greater diversity of offerings and services within the supplement channel. “We have long regarded J+D Labs’ reputation and the significance of what they bring to the table as a leader in the industry,” he said. J+D Labs’ extensive experience manufacturing a wide-range of softgels, specialized tablets, capsules, and powder formulations was a perfect complement to Captek’s offerings. Wood stated, “Going forward, we are committed to our collective success through focusing on our customers, sharing best practices, and continuing our best-in-class quality and compliance standards.”
“This acquisition is positive for everyone: for our employees, our suppliers, our customers, and the end-users,” said J+D Labs owner, Jay Majmudar. CSI is well established in more than 20 countries. “We are happy to play a key role in helping to expand distribution even further. We will continue to make quality, price, and timely delivery a top priority,” emphasized Majmudar.
The newly joined companies will continue to produce high quality products in both Cerritos and Vista, CA. This will give customers the business continuity planning they have long sought by having the ability to have their products manufactured at either site. As a result, more than 300,000 sq ft of manufacturing, warehousing, and analytical testing labs will immediately bring to market greater capacity, expertise, comprehensive turnkey packaging, the benefits of enteric coating, and more.
In the coming months the combined company will work with its customer-facing teams to communicate its newly expanded product and service offerings to both existing and prospective customers.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance